0001725160-22-000142.txt : 20220801
0001725160-22-000142.hdr.sgml : 20220801
20220801172817
ACCESSION NUMBER: 0001725160-22-000142
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220801
FILED AS OF DATE: 20220801
DATE AS OF CHANGE: 20220801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paul Andrea
CENTRAL INDEX KEY: 0001863130
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 221125971
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVENUE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 1710
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 1710
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_165938928345083.xml
FORM 4
X0306
4
2022-08-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001863130
Paul Andrea
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 1710
NEW YORK
NY
10018
0
1
0
0
General Counsel
Stock Option (Right to Buy)
28.82
2022-08-01
4
A
0
290500
0
A
2032-07-31
Common Stock
290500.0
290500
D
The options were granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
/s/ Andrea Paul
2022-08-01